StockWatch
·
NGL FINE-CHEM LTD. · QQ2 FY-2027 · THE CALL

Recovery sustains, margin pressure looms near-term

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsNGLFINENGL FINE-CHEM LTD.18 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade A

Hit Q2 guidance: 32% YoY revenue (prior ₹150 Cr target exceeded), 17.68% EBITDA margin (within 15%-18% range). Long-term targets reaffirmed. No prior misses cited.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong Q2 recovery (32% revenue, 69% PAT growth) validates demand rebound post-inventory normalization and exceeds prior ₹150 Cr quarterly run-rate target. However, sequential margin compression (-11.7% PAT QoQ despite 14% revenue growth) flags near-term cost pressure from new facility ramp, working capital drag, and input inflation. Long-term margin guide (15%-18%) reaffirmed but Europe/US catalysts deferred to 2028-2030. Hold until Phase II utilization ramp and cost normalization materialize.

₹158.7 Cr

Revenue · +32% YoY

₹16.2 Cr

Reported PAT · +68.8% YoY

Compressing

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Q2 revenue ₹158.71 Cr, 32% YoY growth

MET

Delivered ₹158.7 Cr, 32% YoY — matches exactly

EBITDA ₹28.06 Cr with 17.68% margin

MET

OPM 17.7% × ₹158.7 Cr = ₹28.08 Cr EBITDA — matches

PAT ₹16.25 Cr, 69% YoY growth

MET

Delivered ₹16.2 Cr, 68.8% YoY — matches within rounding

Q2 growth driven by volumes, not prices

MET

Analyst pressed; mgmt confirmed substantial part from volumes

EBITDA margin within 15%-18% guided range

MET

17.68% delivered; at high end of guide, corroborates

30%-40% utilization at Phase II over next 2-3 quarters

MET

Management stated explicitly; concrete facility + plan

Sequential PAT decline (-11.7%) despite 14% QoQ revenue growth

MET

Cost inflation, depreciation, inventory carrying costs explain margin compression

Earnings quality

What changed since the last call

Deltas vs. the prior call

Phase II facility now operational

New

Commission completed Sep 2026. Provides incremental capacity; utilization ramp to 30%-40% planned. Near-term margin pressure expected from depreciation + fixed cost absorption.

Europe timeline slips; customer slower than planned

Downgrade

Prior target ₹50-60 Cr from Europe this year likely missed. Mgmt now guides critical mass to 2028-2030. Customer onboarding takes 2-3 yrs post-regulatory approval.

Margin guide maintained, not upgraded

Neutral

Despite 32% YoY growth delivery, mgmt reaffirmed 15%-18% long-term target, not higher. Implies cost base rising in line with or above revenue during facility ramp phase.

Inventory strategy from manufacturing-to-order to manufacturing-to-stock

New

Shifted ~1 year ago. Inventory now ₹118 Cr (Sep) vs ₹70 Cr (March). Expected to normalize over 2-3 qtrs as facility ramps and demand stabilizes.

The Q&A

Analysts probed hard on margin sustainability (Rohit/PMS, Raghuram/Bestpals), price realization (Ishan/Fort), Europe timeline (Dhwani/Turtle), competitive moat (Raghuram/Bestpals). Mgmt held margins at 15%-18% despite growth, defended cost inflation as transient, acknowledged Europe slower than hoped but realistic on 2028-2030 timeline. Tone was defensive on margins but transparent on challenges. No major concessions made.

The exchanges that mattered

Cost inflation & margin pressure — Dhwani Desai, Turtle Capital

Answered

About 50% of new facility staffing in place; operating costs will increase; margin pressure expected near-term. Anticipate easing as utilization ramps.

Price sustainability — Ishan Thakkar, Fort Capital

Answered

Substantial part from volumes. Fluralaner prices down; will likely see further erosion next 6 months, then stabilization. Pricing pressure ongoing.

Depreciation & finance costs — Rahul Jain, Credence Wealth

Answered

Anticipate further depreciation of ~₹3 Cr. Finance costs capped at 20% above current level. Capitalizing assets as deployed.

Phase II utilization ramp — Rohit, PMS

Partial

Cannot estimate FY28 precisely due to market/demand variability. Market performing well; facility occupied with existing + new products. Phase I already contributing materially.

Regulated market margins — Raghuram Kuchi, Bestpals Research

Answered

15%-18% target for unregulated; 18%-22% for regulated. Currently ~95% animal health (mostly unregulated). Regulated markets slower to develop.

Europe/US revenue timing — Raghuram Kuchi, Bestpals Research

Partial

Too early to estimate market share. Objective is register as many products as possible. Lead time 2-3 yrs post-approval. Expect critical mass 2028-2030.

Gross margin trend — Rahul Jain, Credence Wealth

Answered

Long-term 50%-55% range. Currently at upper end. Can move up/down couple percentage points as mix evolves.

Guidance

Forward guidance and management's confidence

FY27 trajectory on track; quarterly stabilization at ₹150 Cr+ achieved

High

Q2 ₹158.7 Cr exceeds prior Q4 FY26 target. Market strong. FY27 full-year trajectory assumed stable.

Long-term EBITDA margins 15%-18% reaffirmed; 18%-22% target for regulated markets

Medium

Q2 delivered 17.68%, within range. Near-term pressure from depreciation (₹3 Cr more ahead), costs, inventory. Timing of easing unclear.

Phase II capex ₹220 Cr total; H1 spent ₹44.05 Cr. Capex to tail off as completion nears.

High

Facility operational (Sep 2026). Remaining capex likely modest finishing touches. No new major capex announced.

Risks the call surfaced

Ranked by how much they should concern a holder

Regulatory approval risk

High

US business entirely contingent on customer filing (Dec 2026) and subsequent audit. First-time audit could flag observations. Europe already slow (9 of 17 approvals); critical mass pushed to 2028-2030.

Working capital / capex intensity

Medium

Inventories jumped from ₹70.28 Cr to ₹118.38 Cr (H1). Strategy shift to manufacturing-to-stock + Gulf War fear spike. Capex ₹44 Cr in H1 consuming cash. Net debt ₹122 Cr (vs ₹108 Cr prior year).

Customer concentration

Medium

Animal health APIs is unregulated market with high concentration. Loss of a large customer or product could materially impact revenue.

Margin compression from new facility ramp

Medium

Phase II adds ₹3 Cr+ annual depreciation; finance costs +20% from prior level. At 30%-40% utilization ramp, fixed costs pressure margins. Sequential PAT -11.7% QoQ on 14% revenue growth flags near-term compression.

Commodity & input cost volatility

Low

Fuel and logistics costs elevated from Gulf War situation; distribution costs nearly doubled. Raw material costs sensitive to global availability. Rupee weakness temporarily aided forex.

Management

Score 7/10. Transparent on challenges (cost inflation, inventory, margin pressure, timeline slips). Clear on strategy (Phase II ramp, regulated market positioning). Some evasion on market size / competitive positioning (asked twice on EU/US addressable market; got 'too early' response). Hit Q2 guidance (32% YoY revenue, 17.68% EBITDA margin within 15%-18% range). Phase II facility on schedule (Sep 2026). Regulatory progress on track (9 of 17 EU filings approved, US veterinary master files filed). No major misses cited.

What to watch next
  • 1 · Q3-Q4 FY27

    Inventory normalization; working capital pressure eases

  • 2 · Dec 2026

    US customer filings complete; inspection may trigger

  • 3 · Dec 2027

    Europe regulatory approvals target (all 17 filings); customer onboarding

Hold until Phase II utilization ramp and cost normalization materialize.

Informational and educational content only. Not investment advice.